Paul Schimmel - Net Worth and Insider Trading

Paul Schimmel Net Worth

The estimated net worth of Paul Schimmel is at least $54 Million dollars as of 2024-04-26. Paul Schimmel is the Director of Alnylam Pharmaceuticals Inc and owns about 306,996 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $44 Million. Paul Schimmel is the Director of Alkermes PLC and owns about 355,600 shares of Alkermes PLC (ALKS) stock worth over $9 Million. Paul Schimmel is also the Director of aTyr Pharma Inc and owns about 1,001,056 shares of aTyr Pharma Inc (LIFE) stock worth over $2 Million. Besides these, Paul Schimmel also holds Tocagen Inc (TOCA) . Details can be seen in Paul Schimmel's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Paul Schimmel has not made any transactions after 2023-05-10 and currently still holds the listed stock(s).

Transaction Summary of Paul Schimmel

To

Paul Schimmel Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Paul Schimmel owns 4 companies in total, including aTyr Pharma Inc (LIFE) , Forte Biosciences Inc (FBRX) , and Alnylam Pharmaceuticals Inc (ALNY) among others .

Click here to see the complete history of Paul Schimmel’s form 4 insider trades.

Insider Ownership Summary of Paul Schimmel

Ticker Comapny Transaction Date Type of Owner
LIFE aTyr Pharma Inc 2023-05-10 director
FBRX Forte Biosciences Inc 2017-04-12 director
ALNY Alnylam Pharmaceuticals Inc 2018-03-13 director
RGEN Repligen Corp 2003-09-10 director

Paul Schimmel Latest Holdings Summary

Paul Schimmel currently owns a total of 4 stocks. Among these stocks, Paul Schimmel owns 306,996 shares of Alnylam Pharmaceuticals Inc (ALNY) as of March 13, 2018, with a value of $44 Million and a weighting of 80.87%. Paul Schimmel owns 355,600 shares of Alkermes PLC (ALKS) as of March 2, 2006, with a value of $9 Million and a weighting of 16.13%. Paul Schimmel also owns 1,001,056 shares of aTyr Pharma Inc (LIFE) as of May 10, 2023, with a value of $2 Million and a weighting of 2.89%. The other 1 stocks Tocagen Inc (TOCA) have a combined weighting of 0.1% among all his current holdings.

Latest Holdings of Paul Schimmel

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALNY Alnylam Pharmaceuticals Inc 2018-03-13 306,996 143.31 43,995,597
ALKS Alkermes PLC 2006-03-02 355,600 24.68 8,776,208
LIFE aTyr Pharma Inc 2023-05-10 1,001,056 1.57 1,571,658
TOCA Tocagen Inc 2017-04-19 2,988 18.90 56,473

Holding Weightings of Paul Schimmel


Paul Schimmel Form 4 Trading Tracker

According to the SEC Form 4 filings, Paul Schimmel has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 27,823 shares on March 13, 2018, which brought Paul Schimmel around $4 Million.

According to the SEC Form 4 filings, Paul Schimmel has made a total of 0 transactions in Alkermes PLC (ALKS) over the past 5 years. The most-recent trade in Alkermes PLC is the sale of 5,000 shares on March 2, 2006, which brought Paul Schimmel around $130,000.

According to the SEC Form 4 filings, Paul Schimmel has made a total of 5 transactions in aTyr Pharma Inc (LIFE) over the past 5 years, including 4 buys and 1 sells. The most-recent trade in aTyr Pharma Inc is the acquisition of 200,000 shares on May 10, 2023, which cost Paul Schimmel around $450,000.

More details on Paul Schimmel's insider transactions can be found in the Insider Trading History of Paul Schimmel table.

Insider Trading History of Paul Schimmel

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Paul Schimmel Trading Performance

GuruFocus tracks the stock performance after each of Paul Schimmel's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul Schimmel is -9.36%. GuruFocus also compares Paul Schimmel's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul Schimmel within 3 months outperforms 5 times out of 22 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Paul Schimmel's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Paul Schimmel

Average Return

-12.28%

Average return per transaction

Outperforming Transactions

33%

7 out of 21 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -2.53 -9.36 -7.47 -12.28 -17.85 -32.76
Relative Return to S&P 500(%) -2.43 -11.83 -11.97 -23.35 -28.47 -45.52

Paul Schimmel Ownership Network

Ownership Network List of Paul Schimmel

No Data

Ownership Network Relation of Paul Schimmel


Paul Schimmel Owned Company Details

What does aTyr Pharma Inc do?

Who are the key executives at aTyr Pharma Inc?

Paul Schimmel is the director of aTyr Pharma Inc. Other key executives at aTyr Pharma Inc include Chief Financial Officer Jill Marie Broadfoot , Chief Medical Officer Sanjay Shukla , and See Remarks Nancy Krueger .

aTyr Pharma Inc (LIFE) Insider Trades Summary

Over the past 18 months, Paul Schimmel made 1 insider transaction in aTyr Pharma Inc (LIFE) with a net purchase of 200,000. Other recent insider transactions involving aTyr Pharma Inc (LIFE) include a net purchase of 55,000 shares made by Sanjay Shukla , a net sale of 3,156 shares made by Jill Marie Broadfoot ,

In summary, during the past 3 months, insiders sold 1,590 shares of aTyr Pharma Inc (LIFE) in total and bought 0 shares, with a net sale of 1,590 shares. During the past 18 months, 3,156 shares of aTyr Pharma Inc (LIFE) were sold and 255,000 shares were bought by its insiders, resulting in a net purchase of 251,844 shares.

aTyr Pharma Inc (LIFE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

aTyr Pharma Inc Insider Transactions

No Available Data

Paul Schimmel Mailing Address

Above is the net worth, insider trading, and ownership report for Paul Schimmel. You might contact Paul Schimmel via mailing address: 88 Sidney St, Cambridge Ma 02139.

Discussions on Paul Schimmel

No discussions yet.